JP2025504486A5 - - Google Patents
Info
- Publication number
- JP2025504486A5 JP2025504486A5 JP2024543238A JP2024543238A JP2025504486A5 JP 2025504486 A5 JP2025504486 A5 JP 2025504486A5 JP 2024543238 A JP2024543238 A JP 2024543238A JP 2024543238 A JP2024543238 A JP 2024543238A JP 2025504486 A5 JP2025504486 A5 JP 2025504486A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- vlm
- ktm
- bifunctional compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263301887P | 2022-01-21 | 2022-01-21 | |
| US63/301,887 | 2022-01-21 | ||
| PCT/US2023/060996 WO2023141570A2 (en) | 2022-01-21 | 2023-01-20 | Compounds and methods for the targeted degradation of kras |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504486A JP2025504486A (ja) | 2025-02-12 |
| JP2025504486A5 true JP2025504486A5 (https=) | 2026-01-27 |
Family
ID=87349145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543238A Pending JP2025504486A (ja) | 2022-01-21 | 2023-01-20 | Ｋｒａｓの標的分解のための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250206732A1 (https=) |
| EP (1) | EP4466277A4 (https=) |
| JP (1) | JP2025504486A (https=) |
| WO (1) | WO2023141570A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| TW202440597A (zh) | 2022-11-30 | 2024-10-16 | 美商虎行生物公司 | 含戊二醯亞胺之pan-kras-突變降解劑化合物及其用途 |
| EP4626554A1 (en) | 2022-11-30 | 2025-10-08 | Tiger Biotherapeutics Inc. | Glutarimide-containing kras-mutant degrader compounds and uses thereof |
| WO2024120424A1 (zh) * | 2022-12-07 | 2024-06-13 | 贝达药业股份有限公司 | 一种靶向泛kras蛋白降解剂的化合物及其应用 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| EP4735438A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras |
| EP4735452A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras protein |
| WO2025024732A1 (en) * | 2023-07-26 | 2025-01-30 | Arvinas Operations, Inc. | Compounds useful in the treatment of kras mediated disorders |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025039676A1 (zh) * | 2023-08-18 | 2025-02-27 | 贝达药业股份有限公司 | 一种靶向泛kras蛋白降解剂的化合物及其应用 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025107579A1 (zh) * | 2023-11-20 | 2025-05-30 | 贝达药业股份有限公司 | 一种靶向泛kras蛋白降解剂的化合物及其应用 |
| WO2025168051A1 (zh) * | 2024-02-08 | 2025-08-14 | 润佳（苏州）医药科技有限公司 | 一种双官能化合物及其用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US10646488B2 (en) * | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2019195609A2 (en) * | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US20230002371A1 (en) * | 2019-09-13 | 2023-01-05 | Biotheryx, Inc. | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN115803030A (zh) * | 2020-04-06 | 2023-03-14 | 阿维纳斯企业公司 | 用于kras靶向降解的化合物和方法 |
| WO2023077441A1 (en) * | 2021-11-05 | 2023-05-11 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
-
2023
- 2023-01-20 WO PCT/US2023/060996 patent/WO2023141570A2/en not_active Ceased
- 2023-01-20 US US18/729,843 patent/US20250206732A1/en active Pending
- 2023-01-20 JP JP2024543238A patent/JP2025504486A/ja active Pending
- 2023-01-20 EP EP23743953.4A patent/EP4466277A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025504486A5 (https=) | ||
| JP2018524403A5 (https=) | ||
| US10350206B2 (en) | Benzyl substituted indazoles as BUB1 inhibitors | |
| JP7033079B2 (ja) | 芳香族スルホンアミド誘導体 | |
| JP6121991B2 (ja) | Ｍｋｎｋ１キナーゼ阻害剤としてのアミノ置換イミダゾピリダジン | |
| EP3322694B1 (en) | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors | |
| JP2013510860A5 (https=) | ||
| JP2010511721A5 (https=) | ||
| JP2014513704A5 (https=) | ||
| JP2013520502A5 (https=) | ||
| JP6001049B2 (ja) | Ｍｐｓ−１キナーゼ阻害剤としての置換ベンズイミダゾール類 | |
| JP2012508252A5 (https=) | ||
| JP2015537017A (ja) | アミノイミダゾピリダジン類 | |
| JP2017525730A5 (https=) | ||
| KR20260042557A (ko) | 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체 | |
| CN106414435A (zh) | 氨基‑取代的异噻唑 | |
| EP3194380A1 (en) | Benzyl substituted indazoles as bub1 kinase inhibitors | |
| AU2006272652B2 (en) | 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders | |
| JP2022511477A5 (https=) | ||
| JP2017529353A (ja) | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 | |
| JP2016503414A5 (https=) | ||
| JP2018525425A5 (https=) | ||
| WO2018104307A1 (en) | Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4 | |
| JP2017524013A5 (https=) | ||
| WO2018210729A1 (en) | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor |